Ropivacaine
- Generic Name
- Ropivacaine
- Brand Names
- Naropin
- Drug Type
- Small Molecule
- Chemical Formula
- C17H26N2O
- CAS Number
- 84057-95-4
- Unique Ingredient Identifier
- 7IO5LYA57N
- Background
Ropivacaine is an aminoamide local anesthetic drug marketed by AstraZeneca under the trade name Naropin. It exists as a racemate of its S- and R-enantiomers, although the marketed form is supplied only as the purified S-enantiomer.
- Indication
Ropivacaine is indicated in adult patients for the induction of regional or local anesthesia for surgery or acute pain management.
- Associated Conditions
- Acute Pain, Postoperative pain
- Associated Therapies
- Surgical anesthesia therapy
Ropivacaine After Sternotomy
- First Posted Date
- 2015-05-20
- Last Posted Date
- 2018-04-24
- Lead Sponsor
- Kuopio University Hospital
- Target Recruit Count
- 90
- Registration Number
- NCT02449486
- Locations
- 🇫🇮
Kuopio University hospital, Kuopio, Finland
Intraperitoneal Local Anaesthetic in Bowel Surgery
- First Posted Date
- 2015-05-20
- Last Posted Date
- 2017-03-27
- Lead Sponsor
- Royal Adelaide Hospital
- Target Recruit Count
- 86
- Registration Number
- NCT02449720
- Locations
- 🇦🇺
Royal Adelaide Hospital, Adelaide, South Australia, Australia
Continuous Infusion of Ropivacaine Hydrochloride in Reducing Pain After Surgery in Patients With Bladder Cancer
- Conditions
- Interventions
- First Posted Date
- 2015-05-08
- Last Posted Date
- 2019-04-16
- Lead Sponsor
- University of Southern California
- Registration Number
- NCT02438852
- Locations
- 🇺🇸
USC / Norris Comprehensive Cancer Center, Los Angeles, California, United States
Ropivacaine With Clonidine For Pediatric Rectus Sheath Blocks- The Magic Combination
- First Posted Date
- 2015-05-08
- Last Posted Date
- 2019-07-23
- Lead Sponsor
- Mihaela Visoiu
- Target Recruit Count
- 50
- Registration Number
- NCT02439281
- Locations
- 🇺🇸
Children's Hospital of Pittsburgh of UPMC, Pittsburgh, Pennsylvania, United States
Low Dose IV Dexamethasone in Prolonging Caudal Anesthesia in Children Undergoing Genitourinary Surgery
- First Posted Date
- 2015-05-06
- Last Posted Date
- 2021-05-07
- Lead Sponsor
- Indiana University
- Target Recruit Count
- 8
- Registration Number
- NCT02436265
- Locations
- 🇺🇸
Riley Hospital for Children, Indianapolis, Indiana, United States
Ultrasonography-guided and Surgical Rectus Sheath Block in Single-port Access Laparoscopy
- Conditions
- Interventions
- First Posted Date
- 2015-04-30
- Last Posted Date
- 2015-05-04
- Lead Sponsor
- Chungnam National University Hospital
- Target Recruit Count
- 30
- Registration Number
- NCT02431065
Scalp Nerve Block on Emergence Agitation
- Conditions
- Interventions
- First Posted Date
- 2015-04-28
- Last Posted Date
- 2017-01-25
- Lead Sponsor
- Ajou University School of Medicine
- Target Recruit Count
- 44
- Registration Number
- NCT02428283
- Locations
- 🇰🇷
Ajou University Hospital, Suwon, Gyeongki-do, Korea, Republic of
Interscalene Brachial Plexus Block Combined With Suprascapular Nerve Block
- Conditions
- Interventions
- First Posted Date
- 2015-04-23
- Last Posted Date
- 2020-08-27
- Lead Sponsor
- Chuncheon Sacred Heart Hospital
- Target Recruit Count
- 52
- Registration Number
- NCT02424630
Ropivacaine Through Continuous Infusion Versus Epidural Morphine for Postoperative Analgesia After Emergency Cesarean Section
- First Posted Date
- 2015-04-07
- Last Posted Date
- 2022-11-08
- Lead Sponsor
- University Hospital, Grenoble
- Target Recruit Count
- 101
- Registration Number
- NCT02410317
- Locations
- 🇫🇷
Hôpital Couple Enfant - CHU de Grenoble, Grenoble, France
MIRs03: Paravertebral Block With Ropivacaine Before Breast Cancer Surgery
- First Posted Date
- 2015-04-03
- Last Posted Date
- 2019-07-10
- Lead Sponsor
- Institut Curie
- Target Recruit Count
- 380
- Registration Number
- NCT02408393
- Locations
- 🇫🇷
INSTITUT CURIE - Site Paris, Paris, France
🇫🇷Centre Léon Bérard, Lyon, France
🇫🇷Institut de Cancérologie de Lorraine, Vandoeuvre-les-nancy, France
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.